NOTE: HTA data is currently organized by the original publication. As these data are incorporated into multi-functional Atlases, search and other means of accessing data will be added.

Clinical efficacy and molecular response correlates of the Wee1 inhibitor adavosertib with cisplatin in metastatic triple-negative breast cancer (mTNBC)

Keenan T., Li T., Vallius T., Guerriero J.L., Tayob N., Kochupurakkal B., Davis J., Pastorello R., Tahara R.K., Anderson L., Conway J., He M.X., Shannon E., Godin R.E., Sorger P.K., D’Andrea A., Overmoyer B., Winer E.P., Mittendorf E.A., Van Allen E.*, Shapiro G.I.*, Tolaney S.M.*

Clinical Cancer Research, 2(1), 66-82.

Selective inhibition of the negative cell cycle regulator WEE1 may enhance the efficacy of DNA-damaging agents by reducing DNA damage repair. These are multiplexed cyclic immunofluorescence on paired pre- and post-WEE1 inhibitor tumor biopsies, from the first phase II study assessing the efficacy of the WEE1 inhibitor adavosertib with cisplatin in metastatic triple-negative breast cancer (mTNBC). Among patients with mTNBC treated with 0-1 prior lines, adavosertib combined with cisplatin narrowly missed the prespecified ORR cutoff of > 30%. The finding of immune infiltrated tumors in patients with clinical benefit to therapy requires validation in future studies.

Available images

Data image
Clinical Benefit - Cisplatin Biopsy
Data image
Clinical Benefit - Cis Wee1i Biopsy
Data image
No Clinical Benefit - Cisplatin Biopsy
Data image
No Clinical Benefit - Cis Wee1i Biopsy